A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study

摘要: Purpose To assess the long-term efficacy of a variable-dosing regimen with ranibizumab in Prospective Optical Coherence Tomography (OCT) Imaging Patients Neovascular Age-Related Macular Degeneration (AMD) Treated intraOcular Ranibizumab (PrONTO) Study, patients were followed for 2 years. Design A 2-year prospective, uncontrolled, intravitreal based on OCT. Methods In this open-label, single-center, uncontrolled clinical study, AMD neovascularization involving central fovea and retinal thickness (CRT) at least 300 μm as measured by OCT enrolled to receive 3 consecutive monthly injections (0.5 mg) [Lucentis; Genentech Inc, South San Francisco, California, USA]. During first year, retreatment was performed each visit if any criterion fulfilled such an increase OCT-CRT 100 or loss 5 letters more. second criteria amended include qualitative amount fluid detected using Results Forty 37 completed study. At month 24, mean visual acuity (VA) improved 11.1 ( P Conclusions The PrONTO Study OCT-guided resulted VA outcomes comparable from phase III studies, but fewer required.